RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China

Published:2024-06 Issue:3 Volume:22 Page:102093
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Chen Jinchao^ORCID,Wang Mingchao,Qi Xiaolong,Long Huimin,Qi Nienie,Wu Lingfeng,Ke Mang,Shao Sihai,Li Peng,Chen Yongliang,Wang Wei,Zhu Shaoxing,Qi Xiaoping,Li Gonghui

Publisher

Elsevier BV

Reference28 articles.

1. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer;O'Donnell;J Clin Oncol,2023

2. The evolving treatment landscape of advanced urothelial carcinoma;Andreev-Drakhlin;Curr Opin Oncol,2021

3. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer;Hoimes;J Clin Oncol,2023

4. The evolving landscape of antibody-drug conjugates for urothelial carcinoma;Abel;Clin Genitourin Cancer,2021

5. Enfortumab vedotin in previously treated advanced urothelial carcinoma;Powles;N Engl J Med,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disitamab vedotin (RC48) long-term regimen in a post-nephroureterectomy patient with metastases: a case report;Frontiers in Oncology;2024-09-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP